Fujifilm Corporation has  unveiled plans for an initial $10 million investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture of biopharmaceuticals at its Fujifilm Diosynth Biotechnologies, Billingham, UK location. This perfusion based facility represents the culmination of 3 years of in-house innovation by Fujifilm group companies and includes the introduction of patented, disruptive downstream bioprocessing technology to the biopharmaceutical...